The 3-way competition of Pfizer, Lilly and Astellas in the oral RA treatment

As Pfizer, Lilly and Astellas entered the domestic oral rheumatoid arthritis treatment market, the 3-way competition has been formed.

Astellas Korea was recently approved for a clinical trial on its rheumatoid arthritis candidate treatment ‘ASP015K’ from the Ministry of Food and Drug Safety.

ASP015K is an oral medication having the janus kinase(JAK) inhibitor type, identical to the Pfizer’s r...